ScreenerHero

LNTH Lantheus Holdings, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · lantheus.com
100.19USD+0.23%Mkt Cap: 6.54B $P/E: 24.26

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD
INDV
Indivior Pharmaceuticals, Inc.
$4.25BUSDP/E 12.9

Key Statistics

Company
Market Cap6.54B USD
Enterprise Value6.56B USD
Revenue (TTM)1.56B USD
Gross Profit941.95M USD
Net Income (TTM)233.56M USD
Revenue/Share23.70 USD
Last Price100.19 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.2K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)24.26
P/E (Forward)15.67
PEG—
EV/EBITDA16.72
EV/Revenue4.21
P/S4.19
P/B4.97
EPS (TTM)4.13
EPS (Forward)6.38
52W Range
49.6781% of range111.86
52W High111.86 USD
52W Low49.67 USD
Profitability
Gross Margin61.10%
Oper. Margin25.82%
EBITDA Margin25.20%
Profit Margin15.15%
ROE21.43%
ROA10.49%
Growth
Revenue Growth2.70%
Earnings Growth-0.90%
Cash Flow & Leverage
Operating CF390.14M USD
CapEx (TTM)41.50M USD
FCF Margin29.02%
FCF Yield6.90%
Net Debt31.66M USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.57
Current Ratio3.06
Quick Ratio2.82
Book Value/Sh20.10 USD
Cash/Share9.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)107.74 USD
Upside (mean)+7.5%
Target Range102.50 USD – 115.00 USD
102.50+7.5% to mean115.00
# Analysts8
Ownership
Shares Out.65.30M
Float58.61M
Insiders1.73%
Institutions116.76%
Short Interest
Short Ratio3.4d
Short % Float7.23%
Short % Out.6.18%
Shares Short4.04M
Short (prev mo.)5.12M
Technical
SMA 50100.78 (-0.6%)
SMA 20088.07 (+13.8%)
Beta-0.03
S&P 52W Chg14.58%
Avg Vol (30d)984.74K
Avg Vol (10d)1.07M
Technical Indicators
RSI (14)47.5
MACD-0.3958
MACD Signal-0.4645
MACD Hist.+0.0687
BB Upper101.10 USD
BB Middle100.18 USD
BB Lower99.26 USD
BB Width1.83%
ATR (14)0.6404 USD
Vol Ratio (20d)0.69x